PMID

Data

Article Title

Organization

N-Arylsulfonyl-a-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.

Boehringer Ingelheim Pharmaceuticals

Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.

Bristol-Myers Squibb

Structure activity relationships of fused bicyclic and urea derivatives of spirocyclic compounds as potent CCR1 antagonists.

Astrazeneca

The discovery of BMS-457, a potent and selective CCR1 antagonist.

Bristol-Myers Squibb

Design, synthesis and structure activity relationships of spirocyclic compounds as potent CCR1 antagonists.

Astrazeneca

Spirocyclic compounds, potent CCR1 antagonists.

Astrazeneca

1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.

Chemocentryx

Identification of a sulfonamide series of CCR2 antagonists.

Glaxosmithkline

Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part I.

Astrazeneca

In vivo activity of an azole series of CCR2 antagonists.

Glaxosmithkline

Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors.

University Of Copenhagen

Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.

Bristol-Myers Squibb

Chemokine receptor antagonists.

National Heart And Lung Institute

Potent antagonists of the CCR2b receptor. Part 3: SAR of the (R)-3-aminopyrrolidine series.

Deltagen Research Laboratories (Former Combichem)

Identification of novel series of human CCR1 antagonists.

Tanabe Research Laboratories Usa

A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.

Abbott Laboratories

Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.

Novartis Institutes For Biomedical Research

Discovery of novel non-peptide CCR1 receptor antagonists.

Berlex Biosciences

Design and synthesis of novel CCR3 antagonists.

Roche Palo Alto

Potent adjuvantic activity of a CCR1-agonistic bis-quinoline.

University Of Kansas

CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.

Glaxosmithkline

Design and synthesis of a library of chemokine antagonists.

Novartis Institutes Of Biomedical Research

Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.

Telik

Novel pyrrolidine heterocycles as CCR1 antagonists.

Ligand Pharmaceuticals

A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.

Università

Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.

Genzyme

Spiropiperidine CCR5 antagonists.

Roche Palo Alto

Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists.

Pharmacopeia

Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.

Roche Palo Alto

Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists.

Tanabe Research Laboratories

Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.

Pfizer

Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.

Merck Research Laboratories

Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.

Takeda Pharmaceutical

Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.

Ciimar

Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.

Pharmaceutical Research Institute

BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate.

Bristol Myers Squibb

Novel CCR1 antagonists with improved metabolic stability.

Pfizer

Potent small molecule CCR1 antagonists.

Pfizer

The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template.

Pfizer

Design and Characterization of an Intracellular Covalent Ligand for CC Chemokine Receptor 2.

Leiden Academic Centre For Drug Research

Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists.

Bristol-Myers Squibb

Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.

Merck Research Laboratories

Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.

Merck Research Laboratories

Discovery of a novel CCR3 selective antagonist.

Banyu Tsukuba Research Institute

Design, synthesis, and discovery of a novel CCR1 antagonist.

Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.

Merck Research Laboratories

Inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compounds.

National Cancer Istitute-Frederick Cancer Research And Development Center

Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.

Takeda Chemical Industries

Discovery and optimization of pyrazole amides as antagonists of CCR1.

Boehringer Ingelheim Pharmaceuticals

Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2.

Leiden University

Identification of novel azaindazole CCR1 antagonist clinical candidates.

Boehringer Ingelheim Pharmaceuticals

Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.

Glaxosmithkline

Identification of a novel series of potent and selective CCR6 inhibitors as biological probes.

Takeda Pharmaceutical

Identification and biological evaluation of thiazole-based inverse agonists of ROR?t.

Phenex Pharmaceuticals